Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas

Frustaci, S.; Paoli, Antonino De; Bidoli, Ettore; Mura, N. La; Berretta, Massimiliano; Buonadonna, Angela; Boz, G.; Gherlinzoni, F.

doi:10.1159/000073366

Cited by 167 publications

(99 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From our survival analysis, the median follow-up period was 51 months, which is similar to durations of follow-up reported in previous studies [7][8][9][10][11][12][13][14][15][16][17] . Overall median DFS was 33 months in our study population.…”

Section: Discussionsupporting

confidence: 85%

“…This 4-week period is comparable to the reported 4-week time frame within which chemotherapy was commenced in several previous studies [7][8][9][10][11][12][13][14] . We found tumor grade 3 with size >10 cm showed a non-significant trend toward association with worse OS.…”

Section: Discussionsupporting

confidence: 83%

“…Given the heterogeneity of soft tissue sarcomas, it is difficult to determine the value of prognostic factors and the survival outcomes among the different histological subtypes. In term of adjuvant treatment, the impact of adjuvant chemotherapy treatment on survival in soft tissue sarcoma has been investigated in several phase 3 randomized controlled trials [7][8][9][10] Although those studies found adjuvant chemotherapy effective for improving outcome in soft tissue sarcoma, the efficacy of this adjuvant treatment continues to be debated. Data from meta-analyses and large randomized trials reported by the European sarcoma group indicated postoperative chemotherapy improved relapse-free survival (RFS) in patients with extremity soft tissue sarcoma, but data regarding improvement in OS were conflicting [7][8][9][10][11][12][13][14] The aim of this study was to investigate the clinical characteristics, prognostic factors, survival outcomes, and outcomes of treatment in extremity soft tissue sarcoma patients who underwent complete tumor resection at Siriraj Hospital.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical characteristics and outcomes of extremity soft tissue sarcomas at Thailand’s national tertiary referral center

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and outcomes of extremity soft tissue sarcomas at Thailand’s national tertiary referral center

et al. 2018

View full text Add to dashboard Cite

show abstract

“…One theory regarding how chemotherapy might affect local control is that chemotherapy may affect actively dividing cells at the margins of tumors [19]. Although controversy remains regarding the topic with several articles failing to show an effect on local control [6,7,18], other studies have shown that chemotherapy could benefit patients with sarcoma in terms of better local relapse-free survival and overall survival [9,10,13,21]. The effects could be dependent on the exact agents and dosages.…”

Section: Discussionmentioning

confidence: 99%

Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Fan

Patel

Lewis

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment. The effectiveness of radiation and chemotherapy remains uncertain owing to conflicting results in previous reports. Questions/purposes To review our experience with contemporary multimodality treatment, we asked: (1) What is the disease-specific survival and local relapse-free survival? (2) Does American Joint Commission on Cancer (AJCC) stage, tumor size, or location relate to disease outcome? (3) Does radiation therapy improve local control or survival? (4) Do doxorubicin and ifosfamide improve local control or survival? Methods Between 1990 and 2012, we treated 40 patients for localized, high-grade extraosseous osteosarcoma. In this retrospective study, we could determine the status of 36 patients (90%) either to death or for a minimum of 24 months of followup; four (10%) were lost to followup before 24 months. There were 11 patients with AJCC Stage IIA and 25 with Stage III disease. All patients underwent wide surgical excision. Of the patients with Stage IIA disease, four received radiation and none received chemotherapy. Of the patients with Stage III disease, six received radiation, seven were treated with chemotherapy, and six received radiation and chemotherapy. During the study period, high-dose doxorubicin and ifosfamide was the preferred chemotherapy regimen for patients younger than 60 years with normal cardiac and renal function. Local relapse-free survival and disease-specific survival were determined by Kaplan-Meier analysis using a prospectively maintained institutional database supplemented by information from the institutional tumor registry. The Cox proportional hazard model was used to determine the effect of various factors on local recurrence and patient survival.One of the authors certifies that he (SP), or a member of his or her immediate family, has or may receive payments or benefits, during the study period, an amount of less than USD 10,000 from CytRx (Los Angeles, CA, USA), an amount of less than 10,000 USD from Janssen Pharmaceuticals/Johnson & Johnson (Titusville, NJ, USA), and an amount of USD 10,000-USD 100,000 from Novartis (Basel, Switzerland). All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research 1 editors and board members are on file with the publication and can be viewed on request. Clinical Orthopaedics and Related Research 1 neither advocates nor endorses the use of any treatment, drug, or device. Readers are encouraged to always seek additional information, including FDA-approval status, of any drug or device prior to clinical use. Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained. Results At 5 years, local relapse-free survival was 47% (95% CI, 27%-64%), and disease-spe...

show abstract

“…One of its most important uses is in advanced soft tissue sarcomas where it is used as adjuvant chemotherapy along with doxorubicin [2,3]. The Italian cooperative trial showed 5-year overall survival estimate to be 66.0% and 46.1% for the treatment and the control groups, respectively (p=0.04) [4]. Ifosfamide and doxorubicin are also used with good results in advanced rhabdomyosarcoma.…”

Section: Introductionmentioning

confidence: 99%